MAT2A has been proposed as a therapeutic target in tumors with MTAP gene deletion.333 AG-270 is an oral selective MAT2A inhibitor that selectively inhibits the proliferation of MTAP null cells and effectively reduces the level of SAM in tumor cells in tissue and xenograft tumor models.334 A phase I study is ongoing to evaluate AG-270 in advanced solid tumors and lymphomas (NCT03435250). The gene discussed is MAT2A; the disease is lymphoma.